Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
FDA revokes emergency use authorization for Eli Lilly's bamlanivimab » 16:46
04/16/21
04/16
16:46
04/16/21
16:46
LLY

Eli Lilly

$189.25 /

+3.28 (+1.76%)

The U.S. FDA revoked the…

The U.S. FDA revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment failure, the FDA has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. Therefore, the agency determined that the criteria for issuance of an authorization are no longer met and has revoked the EUA. Reference Link

ShowHide Related Items >><<
LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

Conference/Events
Amyris to host conference call » 16:24
04/16/21
04/16
16:24
04/16/21
16:24
AMRS

Amyris

$15.05 /

-0.66 (-4.20%)

Management holds an…

Management holds an investor update conference call on April 22 at 1 pm. Webcast Link

ShowHide Related Items >><<
AMRS Amyris
$15.05 /

-0.66 (-4.20%)

AMRS Amyris
$15.05 /

-0.66 (-4.20%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
AMRS Amyris
$15.05 /

-0.66 (-4.20%)

  • 09
    Apr
AMRS Amyris
$15.05 /

-0.66 (-4.20%)

AMRS Amyris
$15.05 /

-0.66 (-4.20%)

Hot Stocks
Amgen completes acquisition of Five Prime » 08:26
04/16/21
04/16
08:26
04/16/21
08:26
AMGN

Amgen

$255.02 /

+5.34 (+2.14%)

, FPRX

Five Prime

$38.00 /

+0.015 (+0.04%)

Amgen (AMGN) announced…

Amgen (AMGN) announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (FPRX) for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9B without giving effect to related transaction fees and expenses. Following completion of the merger, Five Prime shares have ceased trading on the Nasdaq Global Select Market.

ShowHide Related Items >><<
FPRX Five Prime
$38.00 /

+0.015 (+0.04%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

04/05/21 Oppenheimer
Amgen price target raised to $275 from $266 at Oppenheimer
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/08/21 Guggenheim
Five Prime downgraded to Neutral from Buy at Guggenheim
03/05/21 Barclays
Amgen price target lowered to $230 from $242 at Barclays
FPRX Five Prime
$38.00 /

+0.015 (+0.04%)

03/05/21 Citi
Amgen acquisition brings 'relatively de-risked' asset, says Citi
03/04/21 Jefferies
Five Prime downgraded to Hold from Buy at Jefferies
FPRX Five Prime
$38.00 /

+0.015 (+0.04%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

  • 13
    Nov
AMGN Amgen
$255.02 /

+5.34 (+2.14%)

FPRX Five Prime
$38.00 /

+0.015 (+0.04%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

FPRX Five Prime
$38.00 /

+0.015 (+0.04%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

Hot Stocks
Twist Bioscience exercises right of first refusal to expand Portland facility » 08:07
04/16/21
04/16
08:07
04/16/21
08:07
TWST

Twist Bioscience

$142.09 /

+0.07 (+0.05%)

Twist Bioscience…

Twist Bioscience announced that it has exercised its right of first refusal to expand the lease for its "Factory of the Future" manufacturing facility near Portland, Oregon. The expanded lease secures an additional approximately 100,000-square-foot facility within the same building as the approximately 110,000-square-foot facility Twist leases. The expansion allows for Twist to build out additional vertical opportunities including DNA data storage or other high value growth product lines, with Twist's financial commitment beginning in 2022.

ShowHide Related Items >><<
TWST Twist Bioscience
$142.09 /

+0.07 (+0.05%)

TWST Twist Bioscience
$142.09 /

+0.07 (+0.05%)

04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
02/05/21 JPMorgan
Twist Bioscience downgraded to Underweight from Neutral at JPMorgan
TWST Twist Bioscience
$142.09 /

+0.07 (+0.05%)

  • 03
    Dec
  • 04
    Jun
TWST Twist Bioscience
$142.09 /

+0.07 (+0.05%)

Syndicate
Synlogic 10M share Spot Secondary priced at $3.00 » 06:37
04/16/21
04/16
06:37
04/16/21
06:37
SYBX

Synlogic

$3.18 /

-0.08 (-2.45%)

SVB Leerink acted as sole…

SVB Leerink acted as sole book running manager for the offering.

ShowHide Related Items >><<
SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

  • 16
    Apr
SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

Hot Stocks
Eli Lilly requests FDA revoke EUA for bamlanivimab 700 mg alone » 06:37
04/16/21
04/16
06:37
04/16/21
06:37
LLY

Eli Lilly

$185.93 /

+2.94 (+1.61%)

, AMGN

Amgen

$255.02 /

+5.34 (+2.14%)

Eli Lilly (LLY) has…

Eli Lilly (LLY) has requested the FDA revoke the Emergency Use Authorization, or EUA, for bamlanivimab 700 mg alone. Lilly made this request due to the evolving variant landscape in the U.S. and the full availability of bamlanivimab and etesevimab together. This request is not due to any new safety concern. This final step in Lilly's transition to only supply bamlanivimab and etesevimab for administration together in the U.S. for the treatment of COVID-19 - as planned with the FDA - follows the modification of contracts with the U.S. government to ensure adequate supply of etesevimab to be used together with bamlanivimab. All sites in the U.S. now have access to obtain doses of etesevimab for administration with bamlanivimab-which together neutralize more of the emerging COVID-19 variants in the U.S. than bamlanivimab alone, including the rapidly growing B.1.427/B.1.429 California strain that currently accounts for 50% of the virus in California and over 10% across a number of additional states. In the U.S., bamlanivimab alone should no longer be administered. However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it. Lilly is not requesting the withdrawal of emergency authorization for bamlanivimab alone in any other jurisdiction at this time. However, its use together with etesevimab, where authorized and available, is preferred over bamlanivimab alone. Lilly, in collaboration with Amgen (AMGN), expects to manufacture sufficient supply of bamlanivimab and etesevimab together to meet global supply needs. Going forward, Lilly will submit only bamlanivimab administered with etesevimab together for authorization globally with a full transition expected by June.

ShowHide Related Items >><<
LLY Eli Lilly
$185.93 /

+2.94 (+1.61%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

LLY Eli Lilly
$185.93 /

+2.94 (+1.61%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
AMGN Amgen
$255.02 /

+5.34 (+2.14%)

04/05/21 Oppenheimer
Amgen price target raised to $275 from $266 at Oppenheimer
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/08/21 Guggenheim
Five Prime downgraded to Neutral from Buy at Guggenheim
03/05/21 Barclays
Amgen price target lowered to $230 from $242 at Barclays
LLY Eli Lilly
$185.93 /

+2.94 (+1.61%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

LLY Eli Lilly
$185.93 /

+2.94 (+1.61%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

LLY Eli Lilly
$185.93 /

+2.94 (+1.61%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

LLY Eli Lilly
$185.93 /

+2.94 (+1.61%)

AMGN Amgen
$255.02 /

+5.34 (+2.14%)

Thursday
Syndicate
Synlogic announces common stock offering, no amount given » 16:05
04/15/21
04/15
16:05
04/15/21
16:05
SYBX

Synlogic

$3.17 /

-0.09 (-2.76%)

Synlogic announced that…

Synlogic announced that it has commenced an underwritten public offering of its common stock. SVB Leerink is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

Hot Stocks
Amyris to acquire EcoFabulous Cosmetics, terms not disclosed » 08:03
04/15/21
04/15
08:03
04/15/21
08:03
AMRS

Amyris

$16.07 /

+0.71 (+4.62%)

Amyris announced that it…

Amyris announced that it has executed a binding term sheet for the acquisition of Gen Z-focused beauty brand, EcoFabulous Cosmetics. The acquisition furthers Amyris's growth and market leadership in clean beauty and complements Amyris's family of consumer brands, consisting of Biossance, Pipette, Rose Inc., JVN, Terasana, and Costa Brazil. Amyris is acquiring a 70% controlling interest in EcoFabulous and expects to grow the Gen Z consumer segment through Amyris's innovative science, sustainable ingredients, clean formulation and direct-to-consumer marketing expertise. Marissa will join Amyris to lead brand innovation and be the Chief Creative Officer for the EcoFabulous brand.

ShowHide Related Items >><<
AMRS Amyris
$16.07 /

+0.71 (+4.62%)

AMRS Amyris
$16.07 /

+0.71 (+4.62%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
AMRS Amyris
$16.07 /

+0.71 (+4.62%)

  • 09
    Apr
AMRS Amyris
$16.07 /

+0.71 (+4.62%)

AMRS Amyris
$16.07 /

+0.71 (+4.62%)

Hot Stocks
PTC Therapeutics announces FIREFISH trial results at AAN virtual meeting » 05:25
04/15/21
04/15
05:25
04/15/21
05:25
PTCT

PTC Therapeutics

$47.90 /

+0.555 (+1.17%)

, RHHBY

Roche

$41.64 /

-0.05 (-0.12%)

PTC Therapeutics (PTCT)…

PTC Therapeutics (PTCT) announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy, or SMA, treated with Evrysdi obtained increases in survival and sustained improvements in achieving key motor milestones, including head control, sitting, rolling over, and further developing towards acquiring the ability to stand, and walk. Data were presented at the 2021 American Academy of Neurology, or AAN, virtual annual meeting. Data from Part 2 of the FIREFISH trial demonstrated that at 24 months of treatment, 93% of infants were alive and 83% were alive without permanent ventilation. There were no new deaths between months 12 and 24. Importantly, infants treated with Evrysdi maintained the ability to feed orally 92% at month 24. Further exploratory data suggests similar maintenance in ability to swallow 95%. In the natural course of the disease, infants with type 1 SMA older than 12 months generally require feeding support. In addition, fewer hospitalizations were observed during the second year of treatment with Evrysdi compared with the natural course of the disease, with 34% not requiring hospitalization during 24 months of treatment. Evrysdi is designed to treat SMA by increasing and sustaining the production of the SMN protein, which is found throughout the body and is critical for maintaining healthy motor neurons and movement. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Evrysdi is marketed in the United States by Genentech, a member of the Roche (RHHBY).

ShowHide Related Items >><<
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

PTCT PTC Therapeutics
$47.90 /

+0.555 (+1.17%)

PTCT PTC Therapeutics
$47.90 /

+0.555 (+1.17%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

PTCT PTC Therapeutics
$47.90 /

+0.555 (+1.17%)

RHHBY Roche
$41.64 /

-0.05 (-0.12%)

RHHBY Roche
$41.64 /

-0.05 (-0.12%)

PTCT PTC Therapeutics
$47.90 /

+0.555 (+1.17%)

Wednesday
Hot Stocks
Medavail says North Texas health system expands technology agreement » 16:06
04/14/21
04/14
16:06
04/14/21
16:06
MDVL

Medavail

$13.36 /

-0.28 (-2.05%)

MedAvail Holdings…

MedAvail Holdings announced that a health system in North Texas has expanded its technology agreement with MedAvail, and has deployed MedAvail's MedCenter technology at 16 emergency and urgent care sites in Texas. Patients visiting these urgent and emergency care sites are able to consult virtually with a system pharmacist and fill their prescriptions at the point of care through the MedCenter, eliminating the need to make a separate trip to a pharmacy. Through MedAvail's Pharmacy Technology segment, the company is able to enhance pharmacy services offered by healthcare providers and retail chains. Enterprise customers can purchase MedAvail's technology in order to provide these solutions under their own brands. "We are proud to offer our software and MedCenter technology to large healthcare systems focused on medication adherence and patient satisfaction," said Dave Rawlins, Chief Commercial Officer at MedAvail. "Quick and convenient access to care is even more critical now than ever. MedAvail's innovative pharmacy technology is adaptable to a number of different environments, enabling our partners to improve ease of medication access without compromising safety."

ShowHide Related Items >><<
MDVL Medavail
$13.36 /

-0.28 (-2.05%)

04/12/21 Cowen
Medavail price target raised to $20 from $18 at Cowen
04/05/21 Cowen
Medavail price target raised to $18 from $17 at Cowen
12/14/20 Lake Street
Medavail initiated with a Buy at Lake Street
12/14/20 Cowen
Medavail initiated with an Outperform at Cowen
MDVL Medavail
$13.36 /

-0.28 (-2.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.